Who Paid My Doc
Ioannis Skaribas
Interventional Pain Medicine Houston, TX Medical Doctor
NPI 1922150945 CMS profile 1271763
11451 Katy Fwy Ste 340, Ste 340, Houston, TX 77079
General payments
$92,174
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$886,525
Through program year 2025, Ioannis Skaribas of Houston, TX is reported in the CMS Open Payments database as having received $92,174 across 1,340 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $886,525 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $34,882 | 90 | |
| 2024 | General | $7,661 | 147 | |
| 2023 | General | $14,926 | 131 | |
| 2022 | General | $7,700 | 599 | |
| 2021 | General | $17,111 | 274 | |
| 2020 | General | $347 | 16 | |
| 2019 | General | $9,547 | 83 |
Beside peers
- Ioannis Skaribas
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Ioannis Skaribas were reported at $34,882. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Ioannis Skaribas | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $9,547 | $684 | $216–$2,079 | $163 |
| 2020 | $347 | $382 | $122–$1,109 | $114 |
| 2021 | $17,111 | $552 | $167–$1,554 | $132 |
| 2022 | $7,700 | $605 | $187–$1,924 | $149 |
| 2023 | $14,926 | $671 | $195–$1,915 | $160 |
| 2024 | $7,661 | $684 | $206–$1,837 | $164 |
| 2025 | $34,882 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 19 drugsPart D claims
1,476
Drug cost
$22,882
Branded share of claims
52.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 632 | $10,075 | |
| Oxymorphone Hcl Er Oxymorphone Hcl | Brand | 12 | $4,615 | |
| Cephalexin | Generic | 155 | $1,152 | |
| Gabapentin | Generic | 106 | $1,065 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 50 | $950 | |
| Butalb-Acetaminoph-Caff-Codein Butalbit/Acetamin/Caff/Codeine | Brand | 11 | $647 | |
| Celecoxib | Generic | 42 | $606 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 40 | $518 | |
| Pregabalin | Generic | 86 | $515 | |
| Hydromorphone Hcl | Generic | 38 | $495 |
The 10 drugs with the highest cost, of 19 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 50 billing codesPaid by Medicare
$367,040
Medicare patients
279
Services billed
2,214
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 36% | |
| Depression | 33% | |
| Diabetes | 30% | |
| Osteoporosis | 23% | |
| Chronic kidney disease | 22% | |
| Heart failure | 19% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1,340 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in Texas
Gabor Racz
Interventional Pain Medicine · Lubbock, TX
Pankaj Mehta
Interventional Pain Medicine · Killeen, TX
Chad Stephens
Interventional Pain Medicine · Southlake, TX
Ankur Khosla
Interventional Pain Medicine · Shenandoah, TX
Brian Rich
Interventional Pain Medicine · Decatur, TX
Brian Bruel
Interventional Pain Medicine · Houston, TX
Related records
Interventional Pain Medicine in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.